Evolent Announces Second Quarter 2026 Results
Evolent Health (NYSE: EVH) reported Q2 2026 results for the three months ended June 30, 2026 and raised 2026 revenue guidance to $2.6 to $2.7 billion and Adjusted EBITDA to $120 to $135 million. The company expects 2027 revenue growth of over 25% and Adjusted EBITDA midpoint at or above $150 million. It also outlined two partnership updates, including a $300 million annualized oncology deal.
How this was made
The 30-second read
Why it matters
This release is a guidance and partnership-driven update: raised 2026 revenue range, tightened Adjusted EBITDA range, and a quantified 2027 outlook tied to Performance Suite care margins, expense reductions, and cash flow conversion. It also adds a new oncology Performance Suite partnership with an expected Dec 2026 launch (subject to regulatory approvals) and a smaller Specialty Technology and Services Suite expansion expected to annualize below $5M.
Market read
Traders can reprice EVH on the combination of raised 2026 revenue guidance, tightened EBITDA guidance, and a quantified 2027 profitability and cash-flow path, plus a concrete partnership launch timeline.
What to watch
Execution risk around regulatory approvals for the Dec 2026 oncology go-live and the pace of Performance Suite margin improvement could be the key swing factors versus the headline growth rates.
Background
Evolent is a healthcare services company focused on specialty care solutions for complex conditions, reporting quarterly results and providing forward guidance.
Ticker impact
Evolent raised 2026 revenue guidance to $2.6 to $2.7B and tightened Adjusted EBITDA to $120 to $135M, plus outlined 2027 outlook.
Likely positive bias for EVH shares into the earnings call, with follow-through dependent on how investors underwrite Medicaid headwinds and the timing of the Dec 2026 oncology launch.
The article discloses multiple forward-looking datapoints (raised revenue, tightened EBITDA, 2027 revenue growth >25%, 2027 Adjusted EBITDA midpoint at or above $150M) and specific partnership launch timing, which are actionable for valuation and positioning. However, it provides limited GAAP/adjusted numeric results in the scraped text, reducing precision on magnitude.
Market effects
Reinforces demand for complex specialty care and AI-led operational models among payers, potentially supporting sentiment toward healthcare services and care-management platforms.
Limited direct regional read-through; partnerships span Medicaid and Medicare across 11 states.
Primarily US payer/provider dynamics; minimal direct global impact.
Counterpoint
The outlook still flags significant Medicaid and membership attrition headwinds, so the market may discount the guidance if margin assumptions prove fragile.
Key entities
- public_companyEvolent Health, Inc.
Announced Q2 2026 results, updated 2026 guidance, and provided 2027 outlook plus partnership launch expectations.
- partnershipOncology Performance Suite partnership (existing advanced imaging client)
Expected to cover ~1.5 million lives across Medicaid and Medicare in 11 states, with launch expected by Dec 2026 subject to regulatory approvals, and ~$300M annualized revenue.
- partnershipSpecialty Technology & Services Suite expansion (regional Blues plan customer)
Agreement to broaden suite usage with new products and additional populations; implementations expected in Q3-Q4 2026 and annualized revenue less than $5M.
